CanSino Biologics Inc has announced that the National Medical Products Administration of China (NMPA) has granted the company approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation (Convidecia Air) to be used as a booster dose.
Utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia, Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.
In addition, Convidecia Air can be stably transported and stored between 2
